Valneva (NASDAQ:VALN) Shares Down 3.5%

Valneva SE (NASDAQ:VALNGet Free Report)’s share price fell 3.5% on Tuesday . The company traded as low as $13.12 and last traded at $13.12. 1,709 shares traded hands during trading, a decline of 77% from the average session volume of 7,308 shares. The stock had previously closed at $13.60.

Analyst Upgrades and Downgrades

Separately, HC Wainwright restated a “buy” rating and set a $22.00 price objective on shares of Valneva in a research report on Thursday, September 7th.

Get Our Latest Stock Report on VALN

Valneva Stock Down 2.1 %

The company has a debt-to-equity ratio of 0.41, a current ratio of 1.48 and a quick ratio of 1.33. The stock’s fifty day moving average is $14.20 and its 200 day moving average is $12.88.

Institutional Inflows and Outflows

A number of institutional investors have recently made changes to their positions in VALN. UBS Group AG bought a new position in shares of Valneva in the 2nd quarter valued at about $31,000. OLD Mission Capital LLC bought a new stake in Valneva in the fourth quarter worth about $34,000. Jane Street Group LLC lifted its stake in Valneva by 85.9% in the first quarter. Jane Street Group LLC now owns 16,584 shares of the company’s stock worth $569,000 after purchasing an additional 7,664 shares during the last quarter. Finally, Bank of America Corp DE bought a new stake in Valneva in the first quarter worth about $858,000. Institutional investors own 18.98% of the company’s stock.

Valneva Company Profile

(Get Free Report)

Valneva SE, a specialty vaccine company, develops, manufactures, and commercializes prophylactic vaccines for infectious diseases with unmet needs. It offers IXIARO, an inactivated Vero cell culture-derived Japanese encephalitis vaccine indicated for active immunization against Japanese encephalitis; DUKORAL, an oral vaccine for the prevention of diarrhea caused by Vibrio cholera and/or heat-labile toxin producing enterotoxigenic Escherichia coli bacterium; and VLA2001, an inactivated whole-virus COVID-19 vaccine.

See Also

Receive News & Ratings for Valneva Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Valneva and related companies with's FREE daily email newsletter.